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ABSTRACT
Introduction: Current strategies for the management
of prostate cancer are inadequate in Australia. We will,
in this study, estimate current service needs and
project the future needs for prostate cancer patients in
Australia.
Methods and analysis: First, we will project the
future prevalence of prostate cancer for 2010e2018
using data for 1972e2008 from the New South Wales
(NSW) Central Cancer Registry. These projections,
based on modelled incidence and survival estimates,
will be estimated using PIAMOD (Prevalence,
Incidence, Analysis MODel) software. Then the total
prevalence will be decomposed into ﬁve stages of care:
initial care, continued monitoring, recurrence, last year
of life and long-term survivor. Finally, data from the
NSW Prostate Cancer Care and Outcomes Study,
including data on patterns of treatment and associated
quality of life, will be used to estimate the type and
amount of services that will be needed by prostate
cancer patients in each stage of care. In addition,
Central Cancer Registry episode data will be used to
estimate transition rates from localised or locally
advanced prostate cancer to metastatic disease.
Medicare and Pharmaceutical Beneﬁts data, linked with
Prostate Cancer Care and Outcomes Study data, will be
used to complement the Cancer Registry episode data.
The methods developed will be applied Australia-wide
to obtain national estimates of the future prevalence of
prostate cancer for different stages of clinical care.
Ethics and dissemination: This study was approved
by the NSW Population and Health Services Research
Ethics Committee. Results of the study will be
disseminated widely to different interest groups and
organisations through a report, conference
presentations and peer-reviewed articles.
INTRODUCTION
Prostate cancer is the most common non-skin
cancer among Australian men with around
19775 cases expected to be diagnosed in
2010.
1 This number is expected to increase
signiﬁcantly due to the growth and ageing of
the population.
2 Moreover, the majority of
prostate cancer patients will live much longer
as a result of earlier detection through
prostate-speciﬁc antigen (PSA) testing and
improved treatment.
3 Therefore, the
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ARTICLE SUMMARY
Article focus
- To describe the statistical models we will develop
to obtain estimates of the future prevalence of
prostate cancer in Australia for each stage of
clinical care.
- To describe how the methods developed will be
used to determine:
i. How many prostate cancer patients will need
medical attention in the near future, and
ii. What types of services they will need.
Key messages
- This study will provide the ﬁrst Australian
estimates of current health service needs and
projections of future needs for prostate cancer
patients.
- This information will be essential for ensuring
that men with prostate cancer have adequate
access to the different types of care they will
require as they move through the disease
trajectory.
Strengths and limitations of this study
Strengths
- Breakdown of prevalence according to health
service needs by patient subgroup
- Development and testing of validated statistical
methods for use in other settings
- Multiple population-based data sources: cancer
registry, a patterns of care study and Medicare
and Pharmaceutical Beneﬁts data.
Limitations
- PIAMOD software has substantial data demands
(requiring detailed specially-formatted input data
including externally modelled survival estimates)
- Numerous decisions are required regarding the best
statistical models for incidence and survival
- Several assumptions are needed regarding the
future trends in incidence and survival.
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Open Access Protocolnumbers of new patients with prostate cancer and years
of life living with cancer will both increase signiﬁcantly
in the future. As a consequence, the demands for health
services will rise substantially. Despite these predictions,
there is little or very limited information about the
current or future service needs of prostate cancer
patients in Australia.
Recent studies
4 5 suggested that there will be an acute
shortage of medical oncologists to care for cancer
patients in the USA within 15 years if this problem is not
dealt with immediately. A similar shortage of cancer care
professionals is evident in Australia.
6 There is, therefore,
a need to take action now to accurately assess future
requirements and ensure a sufﬁcient supply of relevant
medical specialists, oncologists and urological nurses for
the care of cancer patients. In order to adequately
predict the services that will be required, we must know
how many men will be diagnosed with and live with
prostate cancer and need to determine their ongoing
medical requirements. However, due to data limitations
and incomplete coverage of incident cases, the few
studies
7e10 of cancer prevalence in Australia provide
only limited information. Moreover, the resource
requirements for treating newly diagnosed patients are
very different from those for supporting long-term
survivors and those with disease progression. Thus, esti-
mates of cancer prevalence by the relevant stages of care
are required to provide a more meaningful and useful
measure for healthcare planning purposes.
11
In this study, we will develop statistical models to
obtain estimates of the future prevalence of prostate
cancer in Australia for each stage of clinical care. The
treatments required for each of these stages of disease
will be based on data from the NSW Prostate Cancer
Care and Outcomes Study (PCOS) and a literature
review of prostate cancer treatment. The statistical
models will initially be constructed using NSW Central
Cancer Registry (NSWCCR) data. The methods devel-
oped in this study will help determine: (i) how many
prostate cancer patients will need medical attention in
the near future and (ii) what types of services they will
require. This information will be essential for ensuring
that prostate cancer patients have adequate access to the
different types of care they require as they move through
the disease trajectory.
METHODS AND ANALYSIS
Data
To obtain estimates of the future prevalence of prostate
cancer, we will develop statistical models using NSWCCR
data. Cases diagnosed with ﬁrst primary prostate cancers
from 1972 to 2008 in New South Wales (NSW), and
notiﬁed to the NSWCCR, will be included in this study.
The registry data then will be linked, by the Centre for
Health Record Linkage, to death records from the State
Registrar of Births, Deaths and Marriages and the
National Death Index to determine survival status as of
31 December 2009. The Cancer Registry maintains
a record of all cases of cancer diagnosed in NSW resi-
dents since 1972, with notiﬁcations from multiple
sources to maximise case ascertainment, and linkage to
death certiﬁcates. Features of the registry data which
make it an ideal source to estimate future cancer
prevalence include long history of registration, good
coverage of the population, stage information at diag-
nosis and follow-up of survival status of individual cases.
Through the standard notiﬁcation process, the CCR
obtains episode data consisting of subsequent notiﬁca-
tions for a patient after the primary cancer has been
registered.
To estimate the type and amount of services needed
for the management of prostate cancer patients, data
from PCOS will be used to provide details of treatments
received. This unique and highly valuable study with
information on treatment and quality of life covers the
largest population-wide cohort of both prostate cancer
cases (n¼1996) and controls (n¼495) to have been
actively followed for 5 years after diagnosis in Australia
and internationally.
In addition we have linked Medicare (MBS) and
Pharmaceutical Beneﬁts (PBS) data for 85% of these
PCOS cases covering the use of health services for an
8-year period from 2000 to 2008.
Detailed methods of analysis are described in the next
section. Brieﬂy, we will project future prevalence by stage
of care for prostate cancer (2010e2018) using the
Cancer Registry data; then the proportions of patients
requiring different type of treatments, obtained from
the PCOS study, will be applied to the projected preva-
lence to estimate the type and amount of health services
needed. Finally, episode data from the Cancer Registry
will be used to estimate the transition rates from early
stage prostate cancer to metastatic disease. The MBS and
PBS data will be used to complement the episode data
on disease progression from early stage to metastatic
disease, and to complement the PCOS data by providing
the type and length of treatment and updated treatment
information up to 2008.
Methods of analysis
To project cancer prevalence estimates by stage of care,
we will adapt the approach used by Mariotto et al.
11 We
will extend Dr Mariotto’s work in two ways. First, we will
add another stage of care, ‘long-term survivors’, who
require only minor cancer-related resources. Second, we
will incorporate survival by disease stage into the esti-
mation of prevalence in combination with years since
diagnosis. In this way, patient groups in each stage of
care will be more homogeneous for the purpose of
predicting healthcare needs.
Projection of future prevalence
We have estimated the limited duration prevalence
(2006) with the counting method
12 using an SAS
program we developed.
13 This method is considered to
be the most reliable for populations covered by a cancer
registry for a sufﬁcient length of time.
14
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Prevalence projection for prostate cancerFor cancer prevalence projections, we will ﬁrst project
numbers of new cases for a further 10 years using
observed incidence data for 1979e2008 by ﬁtting
age-period-cohort (APC) models.
15 16 The number of
incident cases will be estimated for each set of APC
parameters assuming Poisson distributed incident cases.
These estimated incidence counts from the APC models
will be compared with the observed incidence and the
model chosen will be that which gives the best ﬁt to the
observed data using both graphical assessment and
statistical methods (Akaike Information Criterion).
Second, we will tabulate relative survival estimates by
age group, period of diagnosis and follow-up interval
after diagnosis using standard methods,
17 with data from
the NSWCCR (1972e2008). We will then ﬁt a mixture
model to those tabulated relative survival estimates to
extrapolate survival beyond the observed data
(2010e2018).
18 The mixture models assume that the
population of patients is a mixture of two groups with
different prognoses: ‘cured’ patients with no excess risk
due to the diagnosis of prostate cancer and those
patients bound to die from prostate cancer. Men who are
currently ‘disease free’ but whose prostate cancer will
progress leading to death are in the latter group. The
best model will be chosen using both graphical assess-
ment and statistical methods (based on the differences
between the observed values and the predicted values
from the model).
Finally, prevalence projections will be estimated from
model-based incidence and survival estimates, imple-
mented using PIAMOD (Prevalence, Incidence, Analysis
MODel) software.
19 These projections are based on two
different assumptions: (i) incidence and survival for
prostate cancer will remain constant at the same level as
the most recent 3-year average (as used by Mariotto
et al
11); and (ii) incidence and survival trends in the past
will continue into the future.
Projecting prevalence by stage of care
Patients, according to years since diagnosis and cancer
stage at diagnosis, will be assigned to one of ﬁve stages of
care: initial, continued monitoring, recurrence, last year
of life and long-term survivor. The initial care stage is the
ﬁrst 12 months after diagnosis. The majority (>85%) of
cases in this stage will be those diagnosed with early stage
disease. The last year of life stage will cover the
12 months prior to death. The last year of care will over-
ride the other care stages for cases with short survival;
most of the cases included in this stage will be those with
metastatic cancer. The continued monitoring stage will
include cases who survived the ﬁrst 12 months after
diagnosis but underwent treatment or active monitoring
for disease recurrence. Cases with recurrence are those
patients diagnosed with initially localised disease, but
whose cancer then progresses after initial therapy. Long-
term survivors will be those patients diagnosed more
than 10 years previously and with no evidence of disease
progression or recurrence, requiring less intensive
follow-up.
As treatment for prostate cancer depends heavily on
disease stage at diagnosis and this information from the
cancer registry is incomplete,
3 we will redistribute the
cases coded as having unknown stage (about 50% of
total cases) to either localised stage or regional/distant
spread. In the Cancer Registry data, the 50% of prostate
cancer cases who were coded as having unknown stage
had a 10-year relative survival of 85.5%. The 10-year
relative survival for men with localised stage or regional/
distant spread was 99.6% and 49.8%, respectively. We
proportionally assign cases with unknown stage to
localised stage (approximately 72%) or to regional/
distant spread (28%). When the relative survival esti-
mates for each stage group are applied to the re-assigned
cases, the overall relative survival estimate for those
coded as unknown stage by the Cancer Registry becomes
85.6%. Thus we can be reasonably conﬁdent that the
assignment is valid because the sum of the 10-year
relative survival estimates for the two re-assigned groups
is close to that for the original group with unknown stage
(85.5%).
Testing and validation of the models
We will use historical data to test the models by
comparing the actual prevalence for 2004e2008
obtained from the direct counting method
12 and the
projected numbers from the models using data from
earlier years (1994e2003). We will use sensitivity analysis
to assess the impacts of realistic changes in incidence
and survival in the future on estimates of prevalence. For
example, increased PSA testing plus a lower PSA
threshold for biopsy and increased number of core
samples per biopsy will lead to an increase in incidence
in the future. These changes should also result in stage
shifting towards an earlier stage, and thus survival should
also improve as a result. Advances in treatments in the
future may also increase survival, but improvement is
likely to be incremental according to past experience.
We will model the impact of various cancer control
interventions, including prostate cancer testing and
treatment, on current trends, and future trends based on
different scenarios.
Disease progression model
Limited evidence from international studies estimated
that about a quarter of patients with localised prostate
cancer progress to metastatic disease.
20 We will provide
the ﬁrst Australian evidence on the transition rates from
localised or locally advanced prostate cancer to meta-
static disease, using episode data from the CCR
(consisting of notiﬁcations sent after initial diagnosis).
These episode data are routinely collected but not
routinely reported. MBS and PBS data will be used to
complement the CCR data. For example, a change in
monitoring, testing and referral patterns after radical
prostatectomy and regular PSA tests, such as multiple
PSA tests in a short period followed by consultations with
a urologist or oncologist, may indicate a rising PSA level
and disease recurrence or progression.
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Prevalence projection for prostate cancerPublished studies indicate that of patients undergoing
active surveillance, about 24%e30% subsequently
receive curative treatment during follow-up
21 22 and
among patients who initially had aggressive therapy,
15%e40%
23 24 experience cancer recurrence within
5 years of surgery. These patients need either deferred
curative therapy or salvage radiation therapy and/or
salvage prostatectomy. Therefore, it is important to
include these two groups of patients in the estimation of
service needs for prostate cancer. The disease progres-
sion model will provide estimates of the proportions and
numbers of men requiring these types of services.
Estimation of type of care needed
Finally, we will explore the impact of future prevalence
on the healthcare resources that will be required by
patients at different stages in the natural history of the
disease as follows.
We will ﬁrst obtain the proportions of patients
undergoing different cancer treatments including
surgery, androgen deprivation therapy and radiotherapy
from the completed PCOS study. Literature on the
proportions of prostate cancer patients requiring
different treatments at each stage of their cancer journey
will also be used to estimate the number of patients who
need each treatment including active surveillance.
Routinely available MBS and PBS data will be used to
model changes in the trends for different types of
treatment.
Then we will apply the proportions of patients
requiring surgery, radiotherapy, pathology tests and
other services to the estimated prevalence data to
provide accurate and useful information on future
demands for healthcare. Data on the quality of life of
men with prostate cancer from the PCOS study, partic-
ularly sexual and/or urinary complications and prob-
lems after aggressive therapy, will be used to estimate the
psychosocial and other supportive needs of patients at
different time points after diagnosis of prostate cancer.
We will also explore socio-economic and rural/urban
differences in the use of health services. We will allocate
individual patients into urban or rural residents or into
three categories according to socioeconomic status
25
based on their residential address recorded at the time
of diagnosis. We will address the service needs of those
men from rural or socioeconomic disadvantaged areas to
address issues of equity and access as found in three
recent Australian studies.
26e28
Sensitivity analysis and testing of assumptions
Factors that will inﬂuence future prostate cancer inci-
dence can be categorised into (i) growth and ageing of
the population and (ii) level of PSA testing in the
population. As a result of more established patterns of
routine PSA testing,
29 30 the incidence of prostate cancer
over the next 10 years is unlikely to repeat the pattern of
a sharp increase followed by a decrease seen in the early
to mid-1990s. As an alternative, we will project future
incidence based on the assumption that the current
increase (2003e2008) is likely to continue rather than
the trend of the whole period of 1972e2008.
The results of clinical trials comparing treatment
options for prostate cancer could impact on the day-to-
day practice of prostate cancer management. However,
historical data indicated that most advances in cancer
treatment are incremental. Clinical trials showed that
new treatment for patients with advanced prostate
cancer had only limited beneﬁts, thus the impact of
treatment advances in the short-term future should be
minimal on the prediction of future service needs.
Nevertheless, such changes in treatment and survival will
be closely monitored and allowed for in the models
based on recent and ongoing clinical trials.
ETHICS AND DISSEMINATION
This study was approved by the NSW Population and
Health Services Research Ethics Committee in April
2009 and an amendment requesting an additional
2 years of incidence data and updated survival status was
approved in January 2011. A report will be written and
disseminated widely to cancer care providers, the Pros-
tate Cancer Foundation of Australia, policy makers and
health service planners in NSW. Results of the study will
be presented to different interest groups, using appro-
priate language for each audience. Presentations will be
made to national and international conferences, and
manuscripts will be submitted to peer-reviewed national
and international journals.
DISCUSSION
This study will develop methods to obtain estimates of
the prevalence of prostate cancer by stage of care, and
the resulting type and amounts of services that will be
needed in the future for prostate cancer patients. This
information is critical for the timely assessment of the
resources and infrastructure needed for cancer care
services: for initial diagnosis and treatment, continuing
therapy, treatment of subsequent disabilities and side
effects, screening and treatment for recurrence and
progression, and long-term counselling and support.
This information is important to ensure the adequate
provision of services for all Australian men diagnosed
with prostate cancer. It will help address potentially
widening socio-economic and rural/urban disparities in
prostate cancer outcomes by examining equity issues in
the provision of care for subgroups in the population.
The methods developed will be applied to an Australian-
wide perspective to obtain national estimates of the
future prevalence of prostate cancer for different stages
of clinical care.
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